Collegium Pharmaceutical (FRA:354) Cyclically Adjusted Revenue per Share: €9.87 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:354 Collegium Pharmaceutical Inc FRA:354
78 GF Score
Price €30.80
GF Value €37.66
! 3 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Cyclically Adjusted Revenue per Share?

Collegium Pharmaceutical FRA:354 +3.36% 78 Cyclically Adjusted Revenue per Share is €9.87 as of Mar. 2026. GuruFocus rates FRA:354 with a GF Score™ of 78/100 and a GF Value™ of €37.66. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Collegium Pharmaceutical's adjusted revenue per share for the three months ended in Mar. 2026 was €4.178. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Collegium Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-26), Collegium Pharmaceutical's current stock price is €30.80. Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €9.87. Collegium Pharmaceutical's Cyclically Adjusted PS Ratio of today is 3.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Collegium Pharmaceutical was 4.45. The lowest was 2.34. And the median was 3.27.


Collegium Pharmaceutical  (FRA:354) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Collegium Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.80/9.87
=3.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Collegium Pharmaceutical was 4.45. The lowest was 2.34. And the median was 3.27.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Collegium Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms


Collegium Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Collegium Pharmaceutical Cyclically Adjusted Revenue per Share Chart

Collegium Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 8.18 9.69 10.31

Collegium Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.59 9.32 9.35 10.31 9.87

FRA:354 vs ALVO, PAHC, BIOA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


FRA:354
78GF Score
Collegium Pharmaceutical Inc FRA:354
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Collegium Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Collegium Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.178/330.2130*330.2130
=4.178

Current CPI (Mar. 2026) = 330.2130.

Collegium Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.016 241.428 0.022
201612 0.046 241.432 0.063
201703 0.069 243.801 0.093
201706 0.108 244.955 0.146
201709 0.337 246.819 0.451
201712 0.281 246.524 0.376
201803 1.571 249.554 2.079
201806 1.897 251.989 2.486
201809 1.822 252.439 2.383
201812 1.958 251.233 2.574
201903 1.978 254.202 2.569
201906 1.988 256.143 2.563
201909 1.978 256.759 2.544
201912 1.980 256.974 2.544
202003 1.974 258.115 2.525
202006 1.975 257.797 2.530
202009 1.917 260.280 2.432
202012 1.769 260.474 2.243
202103 1.790 264.877 2.232
202106 1.667 271.696 2.026
202109 1.848 274.310 2.225
202112 0.600 278.802 0.711
202203 2.258 287.504 2.593
202206 3.437 296.311 3.830
202209 3.711 296.808 4.129
202212 3.644 296.797 4.054
202303 3.940 301.836 4.310
202306 2.920 305.109 3.160
202309 3.046 307.789 3.268
202312 2.225 306.746 2.395
202403 3.218 312.332 3.402
202406 3.342 314.175 3.513
202409 3.574 315.301 3.743
202412 4.291 315.605 4.490
202503 5.007 319.799 5.170
202506 4.171 322.561 4.270
202509 4.523 324.800 4.598
202512 4.316 324.054 4.398
202603 4.178 330.213 4.178

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €9.87 mean?
Collegium Pharmaceutical (FRA:354) has a Cyclically Adjusted Revenue per Share of €9.87 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Collegium Pharmaceutical and its competitors.
Is Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share too high?
Collegium Pharmaceutical's current Cyclically Adjusted Revenue per Share is €9.87. Overall, Collegium Pharmaceutical has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share compare to ALVO and PAHC?
Collegium Pharmaceutical's Cyclically Adjusted Revenue per Share of €9.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Collegium Pharmaceutical and its competitors. Collegium Pharmaceutical's current Cyclically Adjusted Revenue per Share is €9.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Collegium Pharmaceutical (FRA:354) has a current Cyclically Adjusted Revenue per Share of €9.87. The stock's GF Value™ is €37.66, compared to a current price of €30.80 — trading 18.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €9.87. Collegium Pharmaceutical's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current Cyclically Adjusted Revenue per Share is €9.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €30.80 is trading 18.2% below its estimated GF Value™ of €37.66.

Key valuation signals for FRA:354:

  • Cyclically Adjusted Revenue per Share: €9.87
  • GF Value™: €37.66 vs. price of €30.80 (18.2% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
78GF Score

Get the complete analysis for FRA:354

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.80
Price
€37.66
GF Value